Budget Amount *help |
¥108,290,000 (Direct Cost: ¥83,300,000、Indirect Cost: ¥24,990,000)
Fiscal Year 2009: ¥15,990,000 (Direct Cost: ¥12,300,000、Indirect Cost: ¥3,690,000)
Fiscal Year 2008: ¥21,320,000 (Direct Cost: ¥16,400,000、Indirect Cost: ¥4,920,000)
Fiscal Year 2007: ¥21,320,000 (Direct Cost: ¥16,400,000、Indirect Cost: ¥4,920,000)
Fiscal Year 2006: ¥21,320,000 (Direct Cost: ¥16,400,000、Indirect Cost: ¥4,920,000)
Fiscal Year 2005: ¥28,340,000 (Direct Cost: ¥21,800,000、Indirect Cost: ¥6,540,000)
|
Research Abstract |
We successfully identified various molecular targets for medicines to cure neuropathic pain. They are related to the lysophospahtidic acid (LPA)-mediated mechanisms underlying injury-induced demyelination, gene regulation, microglia activation and supra-spinal pain. Feed-forward amplification of these mechanisms and epigenetic gene regulation of key pain-related molecules were suggested to underlie the chronic status of neuropathic pain.
|